Risk of subsequent primary lymphoma in a cohort of 69,460 five-year survivors of childhood and adolescent cancer in Europe: The PanCareSurFup study.

Autor: Dudley IM; Center for Childhood Cancer Survivor Studies, Institute of Applied Health Research, University of Birmingham, Birmingham, UK., Sunguc C; Center for Childhood Cancer Survivor Studies, Institute of Applied Health Research, University of Birmingham, Birmingham, UK., Heymer EJ; Center for Childhood Cancer Survivor Studies, Institute of Applied Health Research, University of Birmingham, Birmingham, UK., Winter DL; Center for Childhood Cancer Survivor Studies, Institute of Applied Health Research, University of Birmingham, Birmingham, UK., Teepen JC; Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands., Belle FN; Childhood Cancer Research Group, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.; Center for Primary Care and Public Health (Unisante), University of Lausanne, Lausanne, Switzerland., Bárdi E; St Anna Children's Hospital, Vienna, Austria.; Department of Pediatrics and Adolescent Medicine, Johannes Kepler University Linz, Kepler University Hospital, Linz, Austria., Bagnasco F; Scientific Directorate, IRCCS Istituto Giannina Gaslini, Genova, Italy., Gudmundsdottir T; Danish Cancer Society Research Center, Childhood Cancer Research Group, Copenhagen, Denmark.; Children's Hospital, Landspitali University Hospital, Reykjavik, Iceland., Skinner R; Great North Children's Hospital, Newcastle upon Tyne Hospitals National Health Service Foundation Trust, Newcastle upon Tyne, UK.; Newcastle University Center for Cancer, Newcastle University, Newcastle upon Tyne, UK., Michel G; Department of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland., Byrne J; Boyne Research Institute, Bettystown, Co Meath, Ireland., Øfstaas H; Division of Pediatric and Adolescent Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway., Jankovic M; Pediatric Clinic, University of Milano-Bicocca, Hospital San Gerardo, Monza, Italy., Mazić MČ; University Children's Hospital Ljubljana, University Medical Center Ljubljana, Ljubljana, Slovenia., Mader L; Childhood Cancer Research Group, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland., Loonen J; Department of Hematology, Radboud University Medical Center, Nijmegen, Netherlands., Garwicz S; Department of Clinical Sciences Lund, Pediatrics, Lund University, Skane University Hospital, Lund, Sweden., Wiebe T; Department of Clinical Sciences Lund, Pediatrics, Lund University, Skane University Hospital, Lund, Sweden., Alessi D; Childhood Cancer Registry of Piedmont, Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin, Turin, Italy.; Reference Center for Epidemiology and Cancer Prevention-Piemonte, University Hospital Citta della Salute e della Scienza di Torino, Turin, Italy., Allodji RS; Radiation Epidemiology Team, Center for Research in Epidemiology and Population Health, National Institute of Health and Medical Research Unit 1018, University Paris Saclay, Gustave Roussy, Villejuif, France., Haddy N; Radiation Epidemiology Team, Center for Research in Epidemiology and Population Health, National Institute of Health and Medical Research Unit 1018, University Paris Saclay, Gustave Roussy, Villejuif, France., Grabow D; German Childhood Cancer Registry, Division of Childhood Cancer Epidemiology, Institute of Medical Biostatistics, Epidemiology, and Informatics, Johannes-Gutenberg University Mainz, Mainz, Germany., Kaatsch P; German Childhood Cancer Registry, Division of Childhood Cancer Epidemiology, Institute of Medical Biostatistics, Epidemiology, and Informatics, Johannes-Gutenberg University Mainz, Mainz, Germany., Kaiser M; German Childhood Cancer Registry, Division of Childhood Cancer Epidemiology, Institute of Medical Biostatistics, Epidemiology, and Informatics, Johannes-Gutenberg University Mainz, Mainz, Germany., Maule MM; Childhood Cancer Registry of Piedmont, Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin, Turin, Italy.; Reference Center for Epidemiology and Cancer Prevention-Piemonte, University Hospital Citta della Salute e della Scienza di Torino, Turin, Italy., Jakab Z; Hungarian Childhood Cancer Registry, Second Department of Pediatrics, Semmelweis University, Budapest, Hungary., Gunnes MW; Division of Pediatric and Adolescent Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.; Department of Registration, Cancer Registry of Norway, Oslo, Norway., Terenziani M; Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Zaletel LZ; Division of Radiotherapy, Institute of Oncology, Ljubljana, Slovenia., Kuehni CE; Childhood Cancer Research Group, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.; Division of Pediatric Hematology/Oncology, Department of Pediatrics, University Children's Hospital of Bern, University of Bern, Bern, Switzerland., Haupt R; Diagnosis, Observation, Prevention After Oncologic Treatment (DOPO) Clinic, Division of Hematology/Oncology, IRCCS Istituto Giannina Gaslini, Genova, Italy., de Vathaire F; Radiation Epidemiology Team, Center for Research in Epidemiology and Population Health, National Institute of Health and Medical Research Unit 1018, University Paris Saclay, Gustave Roussy, Villejuif, France., Kremer LC; Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Emma Children's Hospital, Amsterdam, Netherlands., Lähteenmäki PM; Department of Pediatrics and Adolescent Medicine, Turku University and Turku University Hospital, Turku, Finland., Winther JF; Danish Cancer Society Research Center, Childhood Cancer Research Group, Copenhagen, Denmark.; Department of Clinical Medicine, Faculty of Health, Aarhus University and University Hospital, Aarhus, Denmark., Hjorth L; Department of Clinical Sciences Lund, Pediatrics, Lund University, Skane University Hospital, Lund, Sweden., Hawkins MM; Center for Childhood Cancer Survivor Studies, Institute of Applied Health Research, University of Birmingham, Birmingham, UK., Reulen RC; Center for Childhood Cancer Survivor Studies, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Jazyk: angličtina
Zdroj: Cancer [Cancer] 2023 Feb 01; Vol. 129 (3), pp. 426-440. Date of Electronic Publication: 2022 Nov 29.
DOI: 10.1002/cncr.34561
Abstrakt: Background: Survivors of Hodgkin lymphoma (HL) are at risk of developing non-Hodgkin lymphoma (NHL) after treatment; however, the risks of developing subsequent primary lymphomas (SPLs), including HL and NHL, after different types of childhood cancer are unknown. The authors quantified the risk of SPLs using the largest cohort of childhood cancer survivors worldwide.
Methods: The Pan-European Network for Care of Survivors After Childhood and Adolescent Cancer (PanCare) Survivor Care and Follow-Up Studies (PanCareSurFup) cohort includes 69,460 five-year survivors of childhood cancer, diagnosed during 1940 through 2008, from 12 European countries. Risks of SPLs were quantified by standardized incidence ratios (SIRs) and relative risks (RRs) using multivariable Poisson regression.
Results: Overall, 140 SPLs, including 104 NHLs and 36 HLs, were identified. Survivors were at 60% increased risk of an SPL compared with the general population (SIR, 1.6; 95% confidence interval [CI], 1.4-1.9). Survivors were twice as likely to develop NHL (SIR, 2.3; 95% CI, 1.9-2.8), with the greatest risks among survivors of HL (SIR, 7.1; 95% CI, 5.1-10.0), Wilms tumor (SIR, 3.1; 95% CI, 1.7-5.7), leukemia (SIR, 2.8; 95% CI, 1.8-4.4), and bone sarcoma (SIR, 2.7; 95% CI, 1.4-5.4). Treatment with chemotherapy for any cancer doubled the RR of NHL (RR, 2.1; 95% CI, 1.2-3.9), but treatment with radiotherapy did not (RR, 1.2; 95% CI, 0.7-2.0). Survivors were at similar risk of developing a subsequent HL as the general population (SIR, 1.1; 95% CI, 0.8-1.5).
Conclusions: In addition to HL, the authors show here for the first time that survivors of Wilms tumor, leukemia, and bone sarcoma are at risk of NHL. Survivors and health care professionals should be aware of the risk of NHL in these survivors and in any survivors treated with chemotherapy.
(© 2022 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.)
Databáze: MEDLINE
Externí odkaz: